CARDIO-ONCOLOGY – THE NEW KID ON THE BLOCK

  • Ahmed Awais Medical Oncology department, SKMCH&RC, Lahore
  • Irfan A Vaziri Consultant Hematologist & Oncologist Medical Director - Callahan Cancer Center Great Plains Health North Platte, NE
  • Benjamin George Consultant Hematologist & Oncologist Vice Chief of Staff Banner MD Anderson at North Colorado Medical Center Greeley, CO
DOI: https://doi.org/10.37029/jcas.v4i3.200

Abstract

-

References

Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.

Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res 2011;13:R64.

Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063-93.

Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41.

Tan TC, Neilan TG, Francis S, et al. Anthracycline-induced cardiomyopathy in adults. Compr Physiol 2015;5:1517-40.

Gorini S, De Angelis A, Berrino L, et al. Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev 2018;18:7582730.

Berardi D, Agati L. Cardiovascular adverse reactions after the administration of recombinant human erythropoietin: Light and shade. Minerva Cardioangiol 2012;60:227-36.

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-47.

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755-64.

Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European association of cardiovascular imaging and the American society of echocardiography. Eur

Heart J Cardiovasc Imaging 2013;14:721-40.

Barros-Gomes S, Herrmann J, Sharon L, et al. Rationale for setting up a cardio-oncology unit: Our experience at mayo clinic. Cardio Oncol 2016;2:5.

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J 2016;37:2768-801.

Kostakou PM, Kouris NT, Kostopoulos VS, et al. Cardio-oncology: A new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev 2019;24:91-100.

Sharalaya Z, Collier P. Prevention of cardiotoxicities with traditional and novel chemotherapeutic agents. Curr Heart Fail Rep 2018;15:260-9.

Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-oncology services: Rationale, organization, and implementation: A report from the ESC cardio-oncology council. Eur Heart J 2018. Doi: 10.1093/eurheartj/ehy453.

Published
2018-09-30
How to Cite
1.
Awais A, Vaziri IA, George B. CARDIO-ONCOLOGY – THE NEW KID ON THE BLOCK. J Cancer Allied Spec [Internet]. 2018Sep.30 [cited 2024Nov.25];4(3). Available from: https://jcas.journals.publicknowledgeproject.org/index.php/jcas/article/view/200
Issue
Vol 4 No 3 (2018): Journal of Cancer & Allied Specialties
Section
Editorial
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.

Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.

Crossref
Scopus
Google Scholar
Europe PMC